Genmark Diagnostics (GNMK) Osake Kurssi
Genmark Diagnostics Kurssi
Liikevaihto on kasvanut 59,2 % vuodessa viimeisten 12 vuoden aikana 171,55 M USD:een. Genmark Diagnosticsn nettomarginaali on nyt −10,9 %, noussut −102,7 %:sta muutama vuosi sitten.
Genmark Diagnostics osakekurssi
Genmark Diagnostics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Genmark Diagnostics -osakkeesta
Genmark Diagnostics Inc. operates with a business model focused on developing molecular diagnostic solutions. The company primarily specializes in the design, manufacturing, and marketing of diagnostic testing systems. Genmark's products are engineered to deliver accurate and timely results for detecting various infectious diseases and genetic conditions. Their solutions are designed to be flexible, providing rapid and comprehensive testing capabilities for a wide range of clinical applications. With a strong emphasis on innovation and advanced technology, Genmark Diagnostics Inc. aims to provide healthcare professionals with the tools they need to enhance patient care and improve overall outcomes.
Genmark Diagnostics Inc is primarily active in the healthcare and life sciences industries.
The main competitors of Genmark Diagnostics Inc in the market include Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation, and Roche Holding AG.
Genmark Diagnostics Inc, founded in 1993, is a leading provider of molecular diagnostic solutions. It specializes in developing and commercializing multiplex molecular tests, automation platforms, and software analytics. The company's innovative solutions enable healthcare providers to quickly and accurately diagnose multiple diseases, including respiratory infections, gastrointestinal infections, and sepsis. Genmark Diagnostics Inc has a strong track record of delivering high-quality testing solutions, enabling hospitals and laboratories to improve patient care and outcomes. With a dedicated team and a commitment to advancing molecular diagnostics, Genmark Diagnostics Inc continues to drive innovation and shape the future of diagnostic testing.
Genmark Diagnostics Inc has achieved several significant milestones. The company has consistently demonstrated its commitment to innovation and excellence in the field of molecular diagnostics. Notably, Genmark Diagnostics Inc received FDA clearance for its ePlex® Blood Culture Identification Gram-Negative (BCID-GN) Panel, offering rapid and accurate identification of bloodstream infections caused by gram-negative bacteria. In addition, the company has successfully expanded its global presence by obtaining regulatory approvals and entering strategic partnerships in various regions. Genmark Diagnostics Inc has also received recognition for its pioneering technologies and has been honored with prestigious industry awards. These achievements showcase the company's dedication to transforming patient care through cutting-edge diagnostic solutions.
Genmark Diagnostics Inc is primarily present in the United States.
Genmark Diagnostics Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy focused on developing and delivering high-impact molecular diagnostic solutions, Genmark aims to address critical testing needs in the healthcare industry. By leveraging advanced technologies and expertise, the company strives to enhance patient care through accurate and timely diagnostics. Genmark Diagnostics Inc's dedication to driving meaningful advancements in molecular testing and improving patient outcomes stands as a testament to their commitment to excellence in the field of diagnostic medicine.
Genmark Diagnostics Inc is a leading company in molecular diagnostics that offers innovative solutions for healthcare. The company was founded in 1993 and is headquartered in Carlsbad, California. Genmark specializes in the development of molecular diagnostic devices and test kits for medical diagnostics. Its business model includes the sale of diagnostic devices, development and sale of test kits, and diagnostic-related services. Genmark offers two diagnostic systems, the XT-8 and ePlex, which provide fast and accurate diagnosis of infectious diseases and genetic mutations. In addition, the company offers a wide range of test kits for various infections and provides diagnostic services such as clinical consultation and training. Genmark is also actively involved in research and development of new diagnostic devices and test kits tailored to customer and patient needs. Overall, the company aims to offer innovative solutions and services in healthcare, focusing on rapid and accurate diagnosis of infections and genetic mutations.
Liikevaihtoa ei voida laskea Genmark Diagnostics:lle tällä hetkellä.
Voittoa ei voida laskea Genmark Diagnostics:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Genmark Diagnostics:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Genmark Diagnostics:lle tällä hetkellä.
Genmark Diagnostics:n Eulpool-laatuscore on 4/10.
Genmark Diagnostics:n ISIN on US3723091043. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Genmark Diagnostics:n WKN on A1CVZA. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Genmark Diagnostics:n ticker on GNMK. Tämä pörssinoteeraus käytetään Genmark Diagnostics-osakkeiden kauppaan pörssissä.
Genmark Diagnostics osake
Genmark Diagnostics vertaisryhmä
Genmark Diagnostics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Genmark Diagnostics:sta
Meidän osakeanalyysimme Genmark Diagnostics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Genmark Diagnostics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: